Janagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, a class of pharmaceutical agents that functions by increasing urinary glucose excretion to help manage blood glucose levels in patients… Read more
Janagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, a class of pharmaceutical agents that functions by increasing urinary glucose excretion to help manage blood glucose levels in patients with type 2 diabetes. Within this category, laboratories find essential tools for rigorous analytical testing and quality control protocols, including the active pharmaceutical ingredient and its deuterated analogue, Janagliflozin-d4. As a stable isotope-labelled reference standard, this deuterated compound is vital for accurate impurity profiling and quantitative analysis in complex matrices. Pharmaceutical scientists and analytical chemists rely on these high-quality materials to validate assay performance, confirm method specificity, and ensure precise measurement of the parent drug during stability testing and the analysis of finished dosage forms. These reference standards provide the necessary benchmarks to meet regulatory requirements for drug development and manufacturing quality assurance.